Infusion of donor lymphocytes after stem cell transplantation for AML/MDS

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effects of adding innate donor lymphocyte infusion (iDLI) to the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) who have undergone allogeneic hematopoietic stem cell transplantation (HSCT). The study aims to improve transplant outcomes by evaluating the impact of iDLI on acute graft-versus-host disease (GVHD), relapse rates, and overall survival. Participants will receive iDLI early after transplantation to enhance the graft-versus-leukemia (GVL) effect while minimizing the risk of GVHD. The trial includes patients aged 18 and older who meet specific eligibility criteria.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnoses: AML, MDS
* Age: ≥18 years
* Graft type: PBSC
* Donor: ≥18 years
* Informed consent from both donor and recipient

Exclusion Criteria:

• Donors with need for central venous access for the leukapheresis procedure

Where it's running

• Copenhagen University Hospital, Rigshospitalet
  Copenhagen, Denmark Recruiting

Study contacts

• Study coordinator: Lia Minculescu, MD, PhD
• Email: lia.minculescu@regionh.dk
• Phone: +4535457958

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Treatment for relapsed or refractory MDS and AML using Danvatirsen and Venetoclax

  This study is testing a new treatment using Danvatirsen alone and then with Venetoclax to see if it can help people with relapsed or hard-to-treat myelodysplastic syndromes or acute myeloid leukemia.

  Recruiting at 2 sites Phase 1 Montefiore Medical Center · The Bronx, New York and 1 other locations · NCT05986240

• CD123-CAR T-cell therapy for treating acute myeloid leukemia and related conditions

  This study is testing a new type of T-cell therapy to see if it can safely help young people with certain types of leukemia and related blood disorders.

  Recruiting at 2 sites Phase 1 St. Jude Children's Research Hospital · Memphis, Tennessee and 1 other locations · NCT04318678

• Ropeginterferon Alfa-2b added to azacitidine in TP53-mutant MDS/AML

  This study tests whether adding ropeginterferon alfa-2b to azacitidine helps people with TP53-mutant MDS/AML, by finding an effective dose and looking for tumor response.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT07646821

• Registry of patient characteristics and outcomes in acute myeloid leukemia

  This study is gathering information from adults with newly diagnosed or returning acute myeloid leukemia to see how different factors affect their treatment and survival over time.

  Recruiting at 86 sites University of Ulm · Graz and 93 other locations · NCT01252485

• CLN-049 treatment for patients with relapsed or refractory AML or MDS

  This study is testing a new treatment called CLN-049 to see if it can help patients with relapsed or hard-to-treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS).

  Recruiting at 9 sites Phase 1/2 Cullinan Therapeutics Inc. · Birmingham, Alabama and 16 other locations · NCT05143996

• Proton total marrow irradiation before allogeneic transplant for high-risk AML or MDS

  This trial tests whether adding proton-based total marrow irradiation to standard chemotherapy conditioning before allogeneic stem cell transplant can improve outcomes for adults with high-risk or relapsed/refractory AML or MDS.

  Recruiting at 2 sites Phase 1/2 Institute of Hematology and Blood Transfusion, Czech Republic · Prague and 1 other locations · NCT07532824

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.